Drug · CHEMBL3545366

VOXTALISIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. VOXTALISIB. Drugs and targets, record CHEMBL3545366. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545366

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: VOXTALISIB; ChEMBL
ChEMBL ID: CHEMBL3545366; ChEMBL
Type: Small molecule; ChEMBL
Other names: SAR-245409, SAR245409, XL-765, XL765; ChEMBL
DrugBank: DB12400; DrugBank
InChIKey: RGHYDLZMTYDBDT-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Phase 2, for 5 of its 11 diseases, from ClinicalTrials.gov; Open Targets

Targets9

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
MTOR	Serine/threonine-protein kinase mTOR	Serine/threonine-protein kinase mTOR inhibitor	INHIBITOR	https://conductscience.org/library/genes/2475
PIK3CA	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5290
PIK3CB	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5291
PIK3CD	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5293
PIK3CG	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5294
PIK3R1	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5295
PIK3R2	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/5296
PIK3R3	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/8503
PIK3R5	PI3-kinase class I	PI3-kinase class I inhibitor	INHIBITOR	https://conductscience.org/library/genes/23533

Source ChEMBL

Diseases11

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
B-cell chronic lymphocytic leukemia	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004948
glioblastoma	Phase 1	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0018177
mantle cell lymphoma	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0018876
anaplastic astrocytoma	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0016684
borderline ovarian serous tumor	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0020662
breast cancer	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0007254
diffuse large B-cell lymphoma	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0018905
follicular lymphoma	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0018906
grade III glioma	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0021640
lymphoma	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005062

1 to 10 of 11Source Open Targets

See all 11 diseases

Trials11

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01390818	Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1	146	2017-03-07	sar245409	Its name	ClinicalTrials.gov
NCT01936363	Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer	Phase 2	65	2017-04-07	sar245409	Its name	ClinicalTrials.gov
NCT01587040	Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen	Phase 1/2	61	2019-06-11	SAR245409	Its name	ClinicalTrials.gov
NCT01403636	A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia	Phase 2	167		voxtalisib	Its name	ClinicalTrials.gov
NCT00485719	Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors	Phase 1	83		XL765	Its name	ClinicalTrials.gov
NCT00777699	Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors	Phase 1	80		xl765	Its name	ClinicalTrials.gov
NCT01082068	Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer	Phase 1/2	72		xl765	Its name	ClinicalTrials.gov
NCT00704080	A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas	Phase 1	54		xl765	Its name	ClinicalTrials.gov
NCT01596270	A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma	Phase 1	49		SAR245409	Its name	ClinicalTrials.gov
NCT01240460	Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection	Phase 1	40		SAR245409	Its name	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Pimasertib (Once Daily) Plus SAR245409 vs Pimasertib (Twice Daily) Plus SAR245409 Placebo: serious adverse events	16 of 32	18 of 32	64	NCT01936363

Source Trial comparisons

Papers from its trials1

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
29550382	DERIVED	1

Source PubMed

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL3545366

GET https://conductscience.org/api/drugs/v1/CHEMBL3545366/targets

API reference For AI assistants